INTRODUCTION
Phosphorylation of MLC 20 (20 kDa [1] [2] [3] . Despite a rapid decrease in cytosolic Ca 2+ concentration and MLCK activity, MLC 20 phosphorylation and contraction are well maintained. Studies of contraction at fixed Ca 2+ concentrations ('Ca 2+ sensitization') have identified several mechanisms that could explain agonistinduced sustained contraction and MLC 20 phosphorylation [4] [5] [6] [7] . Three essential features characterize these mechanisms: (i) Gprotein activation, (ii) a regulated decrease in MLC phosphatase [PP1c (protein phosphatase 1 catalytic subunit)] activity and (iii) MLC 20 phosphorylation at both Ser 19 and Thr 18 by a Ca 2+ -independent MLCK. The requirement for a Ca 2+ -independent MLCK was evident in studies of vascular smooth muscle where complete inhibition of MLC phosphatase in the absence of Ca 2+ was accompanied by contraction that was sensitive to the nonspecific kinase inhibitor, staurosporine [8] . The existence of a Ca 2+ -independent MLCK that was insensitive to specific inhibitors of Ca 2+ /calmodulin-dependent kinase was first demonstrated by Walsh and co-workers [9] [10] [11] . Two Ca 2+ -independent MLCKs have now been characterized: an ILK (integrin-linked kinase), associated with the myofilaments and spatially distinct from plasma membrane-associated ILK, and ZIP kinase (zipperinteracting protein kinase), which is associated with the MYPT1 (myosin phosphatase targeting subunit 1) and is also known as MYPT1-associated kinase [8] [9] [10] [11] [12] [13] .
Our recent studies have shown that the mechanisms involved in 'Ca 2+ sensitization' also mediate sustained contraction and MLC 20 phosphorylation via G q/13 -coupled receptor agonists [14] [15] [16] . The pathways involve sequential activation of trimeric (G 13 or both G q and G 13 ) and monomeric (RhoA) G-proteins, leading to activation of dual RhoA-dependent pathways. The latter involve a coordinated phosphorylation of two regulatory proteins that inhibit MLC phosphatase activity: MYPT1 and CPI-17 [PKC (protein kinase C) potentiated inhibitor 17 kDa protein]. Phosphorylation of Thr 696 in MYPT1 promotes inhibition of the catalytic subunit (PP1cδ). Phosphorylation of MYPT1 is mediated either directly Abbreviations used: ACh, acetylcholine; Cdc42, cell division cycle 42; CPA, cyclopentyl adenosine; CPI-17, protein kinase C potentiated inhibitor 17 kDa protein; 4-DAMP, 4- [18] [19] [20] [21] [22] .
Both Ca 2+ -independent MLCKs (ZIP kinase and ILK) phosphorylate MLC 20 at both Ser 19 and Thr 18 with equal affinity and induce contraction when added to permeabilized smooth-muscle strips [8] [9] [10] [11] [12] . Previous studies have shown that carbachol, which interacts with G q/13 -coupled muscarinic M 3 receptors, stimulates ZIP kinase activity in bladder smooth muscle [8] . CPI-17 or PHI-1, thiophosphorylated by ILK in vitro, induced contraction when added to Triton X-100 skinned arterial muscle strips; alanine mutants of either CPI-17 or PHI-1 had no effect [22] . However, activation of ILK in vivo by contractile agonists and its involvement in agonist-induced sustained contraction and MLC 20 phosphorylation have not been demonstrated.
Our recent studies have shown that G i -coupled receptors activate PI3K (phosphoinositide 3-kinase) via Gβγ i , but do not activate RhoA in smooth muscle [23, 24] . Because ILK is a known downstream effector of PI3K, we speculated that ILK might be responsible for sustained contraction induced by G i -coupled receptor agonists. G i 1-coupled somatostatin sstr 3 receptors, G i 2-coupled δ-opioid receptors, and G i 3-coupled adenosine A 1 receptors cause an initial transient contraction by activating PLC-β3 (phospholipase C-β3) via Gβγ I , and stimulating IP 3 (inositol 1,4,5-trisphosphate)-dependent Ca 2+ release [25] [26] [27] . In the present study, we show that these agonists elicit a sustained contraction by sequential activation of Gβγ i , PI3K and ILK, resulting in phosphorylation of both CPI-17 and MLC 20 . Although G i 3-coupled muscarinic M 2 receptors activated PI3K, they did not induce MLC 20 phosphorylation or contraction. These receptors triggered preferentially a parallel pathway involving sequential activation of Cdc42 (cell division cycle 42)/Rac1, PAK1 (p21-activated kinase 1) and p38 MAPK (mitogen-activated protein kinase), which resulted in p38 MAPK-dependent inactivation of ILK. Blockade of p38 MAPK activity unmasked M 2 -mediated CPI-17 and MLC 20 phosphorylation and muscle contraction.
MATERIALS AND METHODS

Intestinal smooth-muscle cell culture
Smooth-muscle cells were isolated from the circular muscle layer of rabbit intestine by sequential enzymatic digestion in 25 mM Hepes medium, filtration through 500 µM Nitex, and centrifugation at 350 g, as previously described [14] [15] [16] . Dispersed smooth-muscle cells were cultured in Dulbecco's modified Eagle's medium containing 10 % (v/v) fetal bovine serum until they attained confluence and were then passaged once for use in various studies [14, 16, 23, 24] . ILK-specific siRNA (small interfering RNA) was purchased from Santa Cruz Biotechnology. The siRNA transfection was performed using siRNA transfection reagent and siRNA transfection medium (Santa Cruz Biotechnology) according to the manufacturer's instructions.
ILK and PAK1 immunokinase assays
ILK and PAK1 activities were determined on immunoprecipitates from extracts of cultured muscle cells as described previously [23] . The immunoprecipitates were washed twice with a phosphorylation buffer containing 10 mM MgCl 2 and 40 mM Hepes (pH 7.4) and then incubated for 5 min on ice with 5 µg of MBP (myelin basic protein). ILK activity was also determined using MLC 20 (25 µM) as substrate. Kinase assays were initiated by the addition of 10 µCi of [γ -
32 P]ATP (3000 Ci/mmol) and 20 µM ATP, followed by incubation for 10 min at 37
• C. 32 Plabelled substrate was absorbed on to phosphocellulose discs and free radioactivity was removed by repeated washing with 75 mM phosphoric acid. The extent of phosphorylation was determined from the radioactivity on phosphocellulose discs by liquid-scintillation counting. The results were expressed as c.p.m. per mg of protein in the lysates.
In-gel kinase assay for ILK
ILK activity was also determined by in-gel kinase assay using MBP as the substrate that was co-polymerized with SDS/polyacrylamide gel matrix. Briefly, ILK immunoprecipitates were resolved on an SDS/15 % polyacrylamide gel containing MBP (5 µg/ml of running gel solution). The gels were washed in 50 mM Tris/HCl (pH 7.5) containing 20 % (v/v) propan-2-ol for 60 min to remove SDS and then in 50 mM Tris/HCl and 1 mM DTT (dithiothreitol) for another 60 min. Gels were denatured in 6 M guanidinium chloride solution (50 mM Tris/HCl, 20 mM DTT and 2 mm EDTA) and then renatured with 50 mM Tris/HCl solution containing Tween 20. The gels were pre-incubated in kinase medium containing 20 mM Tris/HCl (pH 7.5), 0.25 mM EGTA and 1 µM calyculin for 60 min and the assay was performed in the same medium containing 300 µM [γ -
32 P]ATP and 5 mM MgCl 2 for another 60 min at 30
• C. The gels were washed extensively with 5 % (w/v) trichloroacetic acid and 1 % sodium phosphate, transferred to nitrocellulose membrane and autoradiographed.
PI3K assay
PI3K was measured by TLC as described previously [23] . Freshly dispersed muscle cells were treated for 10 min with various agonists. After centrifugation for 5 min, 1 ml of lysis buffer [50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 0.1 % SDS, 0.5 % sodium deoxycholate, 2 mM sodium vanadate, 50 mM NaF and protease inhibitor cocktail (10 µg/ml)] was added to the cell suspension and incubation was maintained for 20 min at 4
• C. The cell lysates were precleared by centrifugation, and an aliquot was incubated with 5 µl of anti-PI3K antibody for 2 h at 4
• C, followed by incubation with 30 µl of Protein A/G-Sepharose for 2 h at 4
• C. The immunoprecipitates were washed with lysis buffer and Tris/HCl buffer (20 mM Tris/HCl, pH 7.5) and incubated in a medium containing 1 mg/ml phosphatidylinositol, 20 mM MgCl 2 , 10 µCi of [γ -
32 P]ATP (3000 Ci/mmol) and 20 µM ATP for 10 min at 37
• C. The organic phase containing phosphoinositol phosphates was analysed by TLC and the spots were visualized by autoradiography.
Phosphorylation of MLC 20 , CPI-17 and MYPT1
Phosphorylation of MLC 20 , CPI-17 or MYPT1 was determined by immunoblotting using phospho-specific antibodies to MLC 20 (Ser 19 ), CPI-17 (Thr 38 ) and MYPT1 (Thr 696 ) as described previously [14] . Freshly dispersed or cultured smooth-muscle cells were treated with various agonists for 10 min and solubilized on ice for 1 h in a medium containing 20 mM Tris/HCl (pH 8.0), 1 mM DTT, 100 mM NaCl, 0.5 % SDS, 0.75 % deoxycholate, 1 mM PMSF, 10 µg/ml leupeptin and 100 µg/ml aprotinin. The proteins were resolved by SDS/PAGE and electrophoretically transferred on to PVDF membranes, which were incubated for 12 h with the phospho-specific antibody and then for 1 h with a horseradish peroxidase-conjugated secondary antibody. The bands were identified by enhanced chemiluminescence.
Measurement of contraction in dispersed smooth-muscle cells
Muscle cell contraction was measured in freshly dispersed muscle cells by scanning micrometry as described previously [14, 15] . A cell aliquot containing approx. 10 4 muscle cells/ml was added to 0.1 ml of medium containing various agonists, and the reaction was terminated with 1 % acrolein. The mean length of 50 muscle cells treated with agonist was measured and compared with the mean length of untreated cells, and contraction was expressed as the decrease in mean cell length from control. 
Materials
RESULTS
Sequential activation of PI3K and ILK by G i -coupled receptor agonists
Our previous studies have shown that somatostatin sstr 3 , δ-opioid and adenosine A 1 receptors in smooth-muscle cells are coupled respectively with G i 1, G i 2 and G i 3 [25] [26] [27] activities in freshly dispersed and cultured intestinal smoothmuscle cells (Figures 1 and 2A) . Both activities were abolished by the selective PI3K inhibitor LY294002, implying that ILK was activated downstream of PI3K [28, 29] . ILK activity induced by all three agonists was also inhibited in cells expressing ILK(R211A), but was not affected in cells expressing PKB/Akt(S473A) ( Figure 2B ). ILK activity was time-dependent, reaching a plateau in 5-10 min, and was sustained for at least 20 min (results not shown).
ILK activity was confirmed by in-gel kinase assay using MBP co-polymerized with SDS/polyacrylamide gel matrix ( Figure 3A ) and by immunokinase assay using MLC 20 as substrate (Figure 3C ). The results demonstrate that all three G i -coupled receptor agonists stimulated ILK activity. 20 at Ser 19 and CPI-17 at Thr 38 in vitro [10, 11, 22] . Consequently, the increase in sustained MLC 20 phosphorylation observed in vivo in the present study reflected both direct phosphorylation of MLC 20 by ILK and inhibition of MLC phosphatase by phosphorylated CPI-17.
Sustained muscle cell contraction measured 10 min after addition of each agonist was abolished by pretreatment of the cells for 60 min with pertussis toxin (results not shown) or for 10 min with LY294002 (control contraction: 23 + − 2 to 26 + − 3 µm decrease in cell length; agonist + LY294002: 5 + − 3 to 2 + − 1 µm decrease in cell length), implying that sustained contraction was mediated by G i -dependent activation of PI3K. Sustained contraction was not affected by U73122, Y27632, bisindolylmaleimide, Similarly, sustained MLC 20 phosphorylation induced by DPDPE, somatostatin or CPA was abolished by LY294002 ( Figure 5 ).
The initial transient contraction measured 30 s after addition of each agonist was abolished by pretreatment with pertussis toxin (results not shown), but in contrast with sustained contraction, it was abolished by U73122 and ML-9 [1-(5-chloronaphthalene-1-sulphonyl)-1H-hexahydro-1,4-diazepine hydrochloride] (control contraction: 31 + − 3 to 34 + − 2 µm decrease in cell length; agonist + U73122: 3 + − 4 to 2 + − 4 µm decrease in cell length; agonist + ML-9: 4 + − 5 to 1 + − 2 µm decrease in cell length), implying that it was dependent on PI hydrolysis and Ca 2+ /calmodulin activation of MLCK. The results corroborate previous studies in which all three agonists were shown to stimulate PI hydrolysis and Ca 2+ mobilization via Gβγ i -dependent activation of PLC-β3 [25] [26] [27] . Initial contraction was not affected by LY294002, Y27632, bisindolylmaleimide, PD98059, SB203580, or genistein.
Preferential activation of a distinct pathway by G i 3-coupled muscarinic M 2 receptors
As previously shown [14] , and confirmed in the present study, activation of M 2 receptors did not elicit muscle cell contraction or MLC 20 phosphorylation. The receptors initiated parallel, Gβγ imediated signalling cascades, involving either activation of PLC-β3 or sequential activation of PI3K, Cdc42/Rac1, PAK1 and p38 MAPK [23] . Treatment of cultured smooth-muscle cells with ACh (acetylcholine; 0.1 µM) in the presence of the M 3 receptor antagonist, 4-DAMP (4-diphenylacetoxy-N-methylpiperidine), so as to activate selectively M 2 receptors, stimulated PAK1 but not ILK activity, in contrast with DPDPE, somatostatin-14 and CPA, which stimulated ILK activity but not PAK1 activity ( Figure 6 ). The pattern suggested that M 2 receptors preferentially activate a PI3K/PAK1 pathway, whereas δ-opioid, somatostatin sstr 3 and adenosine A 1 receptors preferentially activate a PI3K/ILK pathway. Expression of ILK(R211A) or siRNA for ILK led to stimulation of PAK1 by δ-opioid, somatostatin sstr 3 and adenosine A 1 receptors, implying that the inability of these receptors to activate a PI3K/PAK1 pathway resulted from suppression of PAK1 activation by ILK ( Figure 6 ). We next examined whether the PAK1/p38 MAPK pathway preferentially activated by M 2 receptors exerted a reciprocal suppression of ILK activity. Blockade of p38 MAPK activity with SB203580 led to activation of ILK via M 2 receptors ( Figure 7A ), and resulted in CPI-17 phosphorylation at Thr 38 ( Figure 8A ) and MLC 20 phosphorylation at Ser 19 ( Figure 8B ) and caused smooth-muscle contraction (Figure 7B) . Phosphorylation of CPI-17 and MLC 20 in the presence of SB203580 was blocked in cells expressing ILK(R211A) (Figure 8) . Thus PAK1 acting via its downstream effector, p38 MAPK, suppressed ILK activity and blocked the ability of M 2 receptors to induce sustained MLC 20 phosphorylation and muscle contraction. Previously, we had shown that phosphorylation of MLCK by PAK1 inactivated MLCK and blocked the ability of M 2 receptors to elicit an initial Ca 2+ -dependent MLC 20 phosphorylation and muscle contraction [14] . 
DISCUSSION
Agonist-induced contraction at fixed Ca 2+ concentration (i.e. Ca 2+ sensitization) involves a Rho-dependent regulated decrease in MLC phosphatase activity, and MLC 20 phosphorylation by a Ca 2+ -independent MLCK. The same mechanisms are responsible for the sustained response to these agonists. Sustained MLC 20 phosphorylation and muscle contraction induced by G q /G 13 -coupled receptor agonists involve sequential activation of RhoGEF (Rho guanine nucleotide-exchange factor) and RhoA, leading to Rho kinase-mediated phosphorylation of MYPT1 and/or PKCmediated phosphorylation of CPI-17, and resulting in inhibition of MLC phosphatase activity [14, 16] . MLC 20 phosphorylation appears to be induced by a Ca 2+ -independent kinase, probably ZIP kinase, recently shown to be activated by the muscarinic agonist, carbachol [8] . The requirement for inhibition of MLC phosphatase via the Rho kinase/MYPT1 and/or PKC/CPI-17 pathways is agonist-specific. A co-ordinated interplay of the two pathways is involved in the sustained response to muscarinic agonists, motilin and sphingosine 1-phosphate, whereas only MYPT1 is involved in the sustained response to endothelin [30] [31] [32] . The latter activates RhoA via ET A receptors (endothelin A receptors) only; concurrent activation of ET B receptors causes dephosphorylation of CPI-17 via sequential activation of p38 MAPK and phosphatase 2A.
The present study characterized the signalling pathways that mediate sustained muscle contraction via G i -coupled receptors that do not activate RhoA, Rho kinase or PKC [24] . Instead, they initiate various pathways dependent on activation of PI3K by Gβγ i [23, [25] [26] [27] . Three G i -coupled receptor agonists used in the present study (DPDPE, somatostatin and CPA) preferentially activated PI3K and ILK, whereas ACh acting via M 2 receptors preferentially activated Cdc42/Rac1, PAK1 and p38 MAPK as shown previously [23] ; p38 MAPK activity was dependent on PAK1 and inhibited by anti-PAK1 antibody [23] . Only the agonists that activated ILK induced sustained MLC 20 phosphorylation and contraction, consistent with ILK acting as a Ca 2+ -independent MLCK that is also capable of inhibiting MLC phosphatase via direct phosphorylation of CPI-17 at Thr 38 [9] [10] [11] 22] . The results of the present study provide the first in vivo evidence that ILK acts as a Ca 2+ -independent MLCK in response to activation of G i -coupled receptors.
The evidence supporting the role of ILK in sustained contraction may be summarized as follows. Agonist-stimulated PI3K and ILK activities and sustained MLC 20 phosphorylation and contraction were inhibited by the PI3K inhibitor LY294002. Furthermore, MLC 20 and CPI-17 phosphorylation was inhibited in cultured smooth-muscle cells expressing ILK(R211A) or treated with siRNA for ILK. Although in vitro studies suggested that ILK could phosphorylate MYPT1 at various sites including the critical inhibitory site (Thr 695 in chicken gizzard MYPT1), we were unable to detect phosphorylation of MYPT1 at Thr 696 in rabbit smooth muscle in vivo [33, 34] . It is possible that only CPI-17 and not MYPT1 is phosphorylated in vivo. Sustained contraction was not affected by MEK, p38 MAPK, Rho kinase, PKC and tyrosine kinase inhibitors, providing further evidence that Rho-dependent pathways were not involved in sustained contraction mediated by G i -coupled receptor agonists. Studies on circular smooth muscle of the cat oesophageal sphincter suggested sequential involvement of ERK1/2 and ILK in PKC-mediated contraction [35] . In the present study, however, neither a MEK inhibitor, PD98059, nor the PKC inhibitor, bisindolylmaleimide, had any effect on sustained contraction.
Initial contraction whether mediated by G q -or G i -coupled receptors involves phosphorylation of MLC 20 by a Ca 2+ /calmodulin-dependent MLCK. The initial contraction can be fully dissociated from sustained contraction, and is selectively suppressed by expression of Gα q or Gα i minigene, by inhibition of PLC-β activity with U73122, which effectively eliminates IP 3 -dependent Ca 2+ release, by calmodulin inhibitors, and by selective inhibitors of Ca 2+ /calmodulin-dependent MLCK [14, 15, [30] [31] [32] . As previously shown and confirmed in the present study, initial contraction induced by DPDPE, somatostatin and CPA was inhibited by pertussis toxin, U73122 and ML-9.
Our previous studies have shown that selective activation of muscarinic M 2 receptors involves sequential activation of Gβγ i3 , PI3K, Cdc42/Rac1, PAK1 and p38 MAPK; the latter was dependent on activation of PAK1 and was inhibited by anti-PAK1 antibody [23] . In the present study, M 2 receptors, but not δ-opioid, somatostatin sstr3 or adenosine A 1 receptors, activated PAK1; conversely, M 2 receptors did not activate ILK or induce CPI-17 and MLC 20 phosphorylation or muscle contraction. The preferential activation of PAK1 and p38 MAPK by M 2 receptors suppressed the PI3K-mediated activation of ILK, since blockade of p38 MAPK activity by SB203580 restored ILK activity as well as CPI-17 and MLC 20 phosphorylation and muscle contraction. Furthermore, the preferential activation of ILK by δ-opioid, somatostatin sstr3 and adenosine A 1 receptors suppressed PAK1 stimulation, since expression of ILK(R211A) and treatment with siRNA for ILK restored PAK1 activity. Thus a reciprocal inhibition between these PI3K-dependent pathways determines the ability of a given G i -coupled receptor to initiate sustained MLC 20 phosphorylation and contraction. What determines the preferential activation of either pathway downstream of PI3K has not been examined. It is worth noting that M 2 receptoractivated PAK1 also inhibits Ca 2+ -dependent MLCK, thereby also suppressing initial contraction [14, 36] . The results provide an explanation for why muscarinic M 2 receptors are not capable of initiating or sustaining smooth-muscle contraction.
In summary, we have identified a novel pathway for sustained smooth-muscle contraction induced by G i -coupled receptor agonists. The pathway involves sequential activation of Gβγ i , PI3K and ILK, resulting in direct phosphorylation of MLC 20 and CPI-17-mediated inhibition of MLC phosphatase. In contrast, G icoupled M 2 receptors engage preferentially a PI3K/PAK1/p38 MAPK pathway that suppresses ILK activity (Scheme 1). Receptors that preferentially engage the PI3K/ILK pathway induce reciprocal suppression of the PAK1/p38 MAPK pathway. 
